CY1105690T1 - Μεθοδοι και σκευασματα για χορηγηση ταξανιων - Google Patents
Μεθοδοι και σκευασματα για χορηγηση ταξανιωνInfo
- Publication number
- CY1105690T1 CY1105690T1 CY20061100438T CY061100438T CY1105690T1 CY 1105690 T1 CY1105690 T1 CY 1105690T1 CY 20061100438 T CY20061100438 T CY 20061100438T CY 061100438 T CY061100438 T CY 061100438T CY 1105690 T1 CY1105690 T1 CY 1105690T1
- Authority
- CY
- Cyprus
- Prior art keywords
- formulations
- administration
- methods
- classes
- taxol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- 229940123237 Taxane Drugs 0.000 abstract 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Μέθοδοι και σκευάσματα για χορήγηση ταξανίων περιγράφονται. Ιδιαίτερα περιγράφονται σκευάσματα ταξόλης διαλυτοποιημένης σε βιταμίνη Ε TPGS, με τον οποίο τρόπο βελτιώνεται η χορήγηση της ταξόλης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7745998P | 1998-03-10 | 1998-03-10 | |
PCT/US1999/005151 WO1999045918A1 (en) | 1998-03-10 | 1999-03-10 | Methods and compositions for delivery of taxanes |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105690T1 true CY1105690T1 (el) | 2010-12-22 |
Family
ID=22138176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061100438T CY1105690T1 (el) | 1998-03-10 | 2006-03-29 | Μεθοδοι και σκευασματα για χορηγηση ταξανιων |
Country Status (17)
Country | Link |
---|---|
US (1) | US20010029264A1 (el) |
EP (1) | EP0977562B8 (el) |
JP (1) | JP2001524988A (el) |
KR (1) | KR20010012363A (el) |
CN (1) | CN1255852A (el) |
AT (1) | ATE314844T1 (el) |
AU (1) | AU762926B2 (el) |
BR (1) | BR9904856A (el) |
CA (1) | CA2288240A1 (el) |
CY (1) | CY1105690T1 (el) |
DE (1) | DE69929313T2 (el) |
DK (1) | DK0977562T3 (el) |
ES (1) | ES2257038T3 (el) |
IL (1) | IL131217A0 (el) |
PT (1) | PT977562E (el) |
WO (1) | WO1999045918A1 (el) |
ZA (1) | ZA991885B (el) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US6040330A (en) * | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
EP1479382A1 (en) * | 1999-06-18 | 2004-11-24 | IVAX Research, Inc. | Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same |
US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
US6828346B2 (en) * | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
JP2003520227A (ja) * | 2000-01-20 | 2003-07-02 | スプラテック ファーマ インコーポレイテッド | 新規なポドフィロトキシン組成物 |
JP2003521545A (ja) * | 2000-02-02 | 2003-07-15 | フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | 改良された溶解性を有するタキサン製剤 |
AU2002239282A1 (en) * | 2000-11-28 | 2002-06-11 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
JP2004520398A (ja) * | 2001-01-18 | 2004-07-08 | ファルマシア・アンド・アップジョン・カンパニー | 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物 |
WO2003045326A2 (en) * | 2001-11-26 | 2003-06-05 | Supergen, Inc | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
KR20040066921A (ko) * | 2001-12-20 | 2004-07-27 | 브리스톨-마이어스스퀴브컴파니 | 생체이용률이 향상된 경구 활성 탁산 유도체의 제약조성물 |
EP1340497A1 (en) * | 2002-03-01 | 2003-09-03 | Novagali Sas | Self emulsifying drug delivery systems for poorly soluble drugs |
AU2003214538A1 (en) * | 2002-03-01 | 2003-09-16 | Novagali Pharma Sa | Self emulsifying drug delivery systems for poorly soluble drugs |
DE60319118T2 (de) * | 2002-07-30 | 2009-02-05 | Wyeth | Parenterale formulierungen mit einem rapamycin hydroxyester |
DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
WO2004050068A1 (en) | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
US20040127551A1 (en) * | 2002-12-27 | 2004-07-01 | Kai Zhang | Taxane-based compositions and methods of use |
JP2006516548A (ja) * | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
WO2004091506A2 (en) * | 2003-04-10 | 2004-10-28 | Ivax Research, Inc. | Taxane-based compositions and methods of use |
EP1498120A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid formulations for the oral administration of taxoids |
EP1510206A1 (en) * | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
BRPI0418427A (pt) * | 2004-01-30 | 2007-06-12 | Pfizer Italia Srl | formulações farmacêuticas de matriz semi-sólida |
WO2005074889A1 (en) * | 2004-02-03 | 2005-08-18 | Dinesh Shantilal Patel | Novel compositions of taxol derivatives and the process for the manufacture thereof |
US7989490B2 (en) | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
US8003122B2 (en) | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
WO2006039268A2 (en) * | 2004-09-30 | 2006-04-13 | Eastman Chemical Company | Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations |
US20070167422A1 (en) * | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
EP2271214B1 (en) * | 2008-03-28 | 2017-05-03 | Particle Sciences, Inc. | Pharmaceutical solutions and method for solubilizing therapeutic agents |
US8409601B2 (en) | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
CN102000052B (zh) * | 2008-06-25 | 2012-12-12 | 重庆市中药研究院 | 紫杉醇及其衍生物在制药中的应用 |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
WO2011038073A1 (en) | 2009-09-23 | 2011-03-31 | Formatech, Inc. | Methods for the preparation of liposomes comprising docetaxel |
US20120065255A1 (en) * | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
EA027666B1 (ru) | 2010-05-03 | 2017-08-31 | ТЕИКОКУ ФАРМА ЮСЭй, ИНК. | Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования |
CN103391770A (zh) * | 2011-01-10 | 2013-11-13 | 细胞基因公司 | 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型 |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
KR102551708B1 (ko) | 2015-06-04 | 2023-07-06 | 크리티테크, 인크. | 수집 장치 및 사용 방법 |
WO2017049083A2 (en) | 2015-09-16 | 2017-03-23 | Dfb Soria, Llc | Delivery of drug nanoparticles and methods of use thereof |
KR20230017354A (ko) | 2016-04-04 | 2023-02-03 | 크리티테크, 인크. | 고형 종양의 치료 방법 |
CN110636833A (zh) | 2017-03-15 | 2019-12-31 | Dfb索里亚有限责任公司 | 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法 |
JP2020523285A (ja) | 2017-06-09 | 2020-08-06 | クリチテック,インコーポレイテッド | 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療 |
US10398646B2 (en) | 2017-06-14 | 2019-09-03 | Crititech, Inc. | Methods for treating lung disorders |
CN111278436A (zh) | 2017-10-03 | 2020-06-12 | 克里蒂泰克公司 | 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症 |
EP3765035A4 (en) | 2018-03-16 | 2021-10-27 | DFB Soria, LLC | TOPICAL THERAPY FOR TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND ETERNAL CANCER USING TAXANNANO PARTICLES |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228162A (en) * | 1979-07-09 | 1980-10-14 | Research Corporation | Dimethyl isosorbide in liquid formulation of aspirin |
US4578391A (en) * | 1982-01-20 | 1986-03-25 | Yamanouchi Pharmaceutical Co., Ltd. | Oily compositions of antitumor drugs |
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
ES2224200T3 (es) * | 1992-11-27 | 2005-03-01 | Mayne Pharma (Usa) Inc. | Composicion inyectable estable de paclitaxel. |
DE59409377D1 (de) * | 1993-10-22 | 2000-06-29 | Hexal Ag | Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator |
US5877205A (en) * | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
-
1998
- 1998-03-10 IL IL13121798A patent/IL131217A0/xx unknown
-
1999
- 1999-03-09 ZA ZA9901885A patent/ZA991885B/xx unknown
- 1999-03-10 AT AT99909941T patent/ATE314844T1/de not_active IP Right Cessation
- 1999-03-10 JP JP54602599A patent/JP2001524988A/ja not_active Ceased
- 1999-03-10 CA CA002288240A patent/CA2288240A1/en not_active Abandoned
- 1999-03-10 EP EP99909941A patent/EP0977562B8/en not_active Expired - Lifetime
- 1999-03-10 PT PT99909941T patent/PT977562E/pt unknown
- 1999-03-10 DK DK99909941T patent/DK0977562T3/da active
- 1999-03-10 CN CN99800022A patent/CN1255852A/zh active Pending
- 1999-03-10 BR BR9904856-6A patent/BR9904856A/pt not_active Application Discontinuation
- 1999-03-10 DE DE69929313T patent/DE69929313T2/de not_active Expired - Fee Related
- 1999-03-10 ES ES99909941T patent/ES2257038T3/es not_active Expired - Lifetime
- 1999-03-10 WO PCT/US1999/005151 patent/WO1999045918A1/en active IP Right Grant
- 1999-03-10 KR KR19997010315A patent/KR20010012363A/ko not_active Application Discontinuation
- 1999-03-10 AU AU29022/99A patent/AU762926B2/en not_active Ceased
-
2001
- 2001-02-28 US US09/795,626 patent/US20010029264A1/en not_active Abandoned
-
2006
- 2006-03-29 CY CY20061100438T patent/CY1105690T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69929313D1 (de) | 2006-03-30 |
ATE314844T1 (de) | 2006-02-15 |
EP0977562B1 (en) | 2006-01-04 |
WO1999045918A1 (en) | 1999-09-16 |
EP0977562A1 (en) | 2000-02-09 |
CA2288240A1 (en) | 1999-09-16 |
US20010029264A1 (en) | 2001-10-11 |
DK0977562T3 (da) | 2006-05-01 |
AU2902299A (en) | 1999-09-27 |
JP2001524988A (ja) | 2001-12-04 |
ES2257038T3 (es) | 2006-07-16 |
PT977562E (pt) | 2006-05-31 |
DE69929313T2 (de) | 2006-08-17 |
KR20010012363A (ko) | 2001-02-15 |
AU762926B2 (en) | 2003-07-10 |
MX9910340A (en) | 2000-04-01 |
CN1255852A (zh) | 2000-06-07 |
IL131217A0 (en) | 2001-01-28 |
EP0977562B8 (en) | 2006-04-26 |
BR9904856A (pt) | 2000-07-18 |
ZA991885B (en) | 1999-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105690T1 (el) | Μεθοδοι και σκευασματα για χορηγηση ταξανιων | |
DK0960107T3 (da) | 6-Thiosubstituerede paclitaxeler | |
BR0102040A (pt) | Uso de paclitaxel estabilizado com albumina para preparação de uma droga para o tratamento de tumores sólidos e a droga desse modo obtida | |
CY1116634T1 (el) | Συζευγματα παραγωγου καλιχεαμυκινης-φορεα | |
DK0762896T3 (da) | Tocopherol-sammensætninger til levering af biologisk aktive stoffer | |
CY1108067T1 (el) | Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης | |
DE60327994D1 (de) | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften | |
CY1105225T1 (el) | Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας | |
CY1112879T1 (el) | Συνθεση εμβολιου | |
SE0003449D0 (sv) | Anticancer compositions | |
CY1105653T1 (el) | Στεροειδεις σαπωνινες για τη θεραπεια της νοσου alzheimer | |
EA200301250A1 (ru) | Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры | |
CY1112682T1 (el) | Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων | |
PT1318791E (pt) | Composicao farmaceutica semi-solida de isotretinoina | |
BR0215184A (pt) | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada | |
CY1105227T1 (el) | Ενωσεις πιπepιδινης ως αντιαλλepγικα | |
CY1111567T1 (el) | Ενδιαμεσα διβενζο (b,f) αζεπινης | |
ATE329903T1 (de) | Hochgradig lipophile camptothecin-derivate | |
CY1112591T1 (el) | Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης | |
DK1543063T3 (da) | Medikament levering | |
DE69938935D1 (de) | Zyklische conotoxin-peptide | |
CY1110449T1 (el) | Συνδυασμος δοκεταξελης και φλαβοπιριδinολης | |
MEP16208A (en) | A combination comprising combretastatin and anticancer agents | |
EA200401250A1 (ru) | Фармацевтические композиции на основе микрочастиц для внутриопухолевого введения | |
CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης |